WHITE PAPER
August 3, 2026
As complex biologics are entering pipelines at a dizzying pace, sponsors and their development partners are facing new challenges in expression, purification, and characterization. Non-standard architectures behave differently than the traditional monoclonal antibodies (mAbs) that defined earlier platform strategies, and without careful planning, programs can be delayed or even sidelined due to low expression and difficult developability.
While conventional platform approaches have accelerated timelines for traditional mAbs by using standardized vectors, templated processes, and minimal early adjustment, these methods often fall short for next-generation architectures. When the underlying molecule falls outside standard platform assumptions, the consequences often emerge later in development, when changes are slower and more costly. What looks like acceleration at the beginning can become a constraint further downstream.
For therapeutic developers seeking both high performance and accelerated timelines, one option is to rely on a single development partner to reduce the number of interfaces and handoffs. That structure can remove certain sources of delay, but it does not eliminate the underlying tension; standardization remains the mechanism that makes those models efficient, though it has limitations when molecules do not conform.
A more effective strategy is to focus on how development activities are connected rather than where they are housed. A pioneering collaboration between Asimov and LOTTE Biologics illustrates how early integration across these functions can accelerate development while reducing risk. By aligning cell line engineering, process development, analytical readiness, and manufacturing strategy from the outset, the partnership enabled a complex antibody program to progress from transfection to drug substance bulk fill in approximately 8.5 months.
This is some text inside of a div block. Great
